What Happened?
Watertown, MA-based EyePoint Pharmaceuticals Appointed Said Saim as Chief Technology Officer
About the Company
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
About the Person
Said Saim is Chief Technology Officer at EyePoint Pharmaceuticals. Previously, Said held various senior IT leadership roles in the industry.
Info Source
Press Release
Short Profile